Introduction to the manufacturing of biologics

Ditte Funding | 12th December 2016

The last decade has seen the rapid growth of biologics in the pharmaceutical market, making them a key sector to watch in the coming years. Biopharma made up 22% of big pharma companies’ sales in 2013, with this number being expected to rise to 32% of sales by 2023. With the growing popularity of these products, it’s important to understand the opportunities and threats they present to pharma companies.

Associate Consultant Ditte Funding takes us through how biologics are made, what makes them unique, and what it all means for pharma companies.

What is a biologic?

Before looking at how to manufacture them, it’s important to first understand what a biologic is. The definition of a biologic isn’t always clear, and what’s considered a biologic is constantly being updated and tweaked as new products are introduced to market. However, the broad definition of a biologic is they are created by either a microorganism or a mammalian cell, and are large, complex molecules; the majority of which are proteins or polypeptides. Examples of biologics include blood or blood products, gene therapies, vaccines, and cell therapies.

There is a significant distinction that needs to be made between traditional small molecule pharmaceuticals (such as aspirin), and biopharmaceuticals. Biologics differ from small molecule drugs in their cost, production, administration, and clinical efficacy. Small molecule drugs are usually chemically synthesised, simple, and have a very well-defined structure. Whereas biologics, or large molecule drugs, are difficult to define and characterise. 

Biologics present great value, as they are highly specific molecules that tend to target more difficult to treat populations; it seems that biologics may become a primary tool for targeting hitherto untreatable diseases. However, in order for biologics to be widely used treatments in the future, they must be manufactured at the right cost and the right scale.

Download the full article with process diagram below

Introducing_orello_Janssen

Using service design to improve patients’ quality of life

Eimear Power | 29th March 2017

Customer Experience Consultant Eimear Power talks through the process of developing Orello, a service for metastatic prostate cancer patients and their loved ones, in collaboration with Janssen.

read more

target-precision-medicine-healthcare-professional-darts

Precision medicine and the changing role of the healthcare professional

Ditte Funding | 23rd March 2017

The growth of precision medicine introduces a shift away from treating the population as a whole, to treating each patient as an individual. How does this change the role of the healthcare professional (HCP) in the patient journey? Associate Consultant Ditte Funding discusses challenges and opportunities.

read more

Black and white - elderly man - face - Blue Latitude Health

Caring for prostate cancer patients

Frances Peters | 15th March 2017

Although not without its challenges, the appropriate care and support available to patients with prostate cancer is gradually evolving. Associate Consultant Frances Peters takes a look at the issues and concerns facing the caregivers of those with prostate cancer. 

read more